Compare GLND & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLND | CRDF |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 86.8M |
| IPO Year | 2026 | 2012 |
| Metric | GLND | CRDF |
|---|---|---|
| Price | $1.40 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | ★ 1.6M | 699.6K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.10 | $0.76 |
| 52 Week High | $12.80 | $3.31 |
| Indicator | GLND | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 36.08 | 54.44 |
| Support Level | $1.10 | $0.87 |
| Resistance Level | $2.44 | $1.13 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 65.26 | 77.83 |
Greenland Energy Co is a Texas energy resources company focused on unlocking Greenland's vast hydrocarbon potential through the application of modern exploration technologies. It holds exclusive licenses to over 2-million acre area in the Jameson Land Basin, where its licenses cover the majority of the basin. The business model for the company is based on exploration and resource development in the frontier basins of Greenland. The company's primary focus is drilling the first wells on the project to conduct the necessary exploration, appraisal and evaluation.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.